Inventiva ADR Dossier
Qualitative Analysis
Business overview
Inventiva S.A. (Euronext Paris and NASDAQ: IVA) is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs. The company's lead product candidate is lanifibranor, an orally administered, next-generation pan-PPAR (peroxisome proliferator-activated receptor) agonist designed to target all three PPAR isoforms (alpha, gamma, and delta). This mechanism uniquely addresses the core biological drivers of MASH progression simultaneously: metabolic dysfunction, inflammation, and fibrosis. Inventiva is currently evaluating lanifibranor in its pivotal NATiV3 Phase 3 clinical trial.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing clinical resources and operational focus on completing the pivotal Phase 3 NATiV3 trial evaluating lanifibranor in adult patients with non-cirrhotic MASH and F2/F3 liver fibrosis.
Expected impact: Aims to establish lanifibranor as a highly differentiated, oral pan-PPAR agonist therapy for MASH, addressing a massive underserved global market.
Narrowing corporate focus and streamlining R&D expenditures by prioritizing the lead MASH program (lanifibranor) and divesting or out-licensing non-core legacy assets.
Expected impact: Extends the company's cash runway into 2027, ensuring sufficient financial flexibility to reach the critical Phase 3 data readout.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides critical non-dilutive growth capital to support the late-stage clinical development of lanifibranor through its pivotal Phase 3 trial and regulatory preparation.
Terms: Claret Capital Partners provided €43 million as part of a larger €130 million committed debt financing package, with an additional uncommitted tranche of up to €20 million.
Collaborative partnership for the development and commercialization of lanifibranor in Greater China.
Terms: Inventiva received a $10 million gross milestone payment in July 2025, alongside $5 million in credit notes recognized under the licensing agreement.
Strategic collaboration to develop and commercialize lanifibranor in Japan and other Asian territories.
Terms: Initiated clinical development in Japan with the dosing of the first participant in a Phase 1 trial, triggering potential future milestone payments and royalties.